Live Breaking News & Updates on Anyue Pomalidomide

Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion
Contribution of Sales of New Products to Revenue Rises to 47.4%
Driving Revenue Up by 16.4%
HONG KONG, May 24, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ( Sino Biopharmaceutical or the Company , together with its subsidiaries, the Group ) (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2021.
Development Highlights
Chia Tai - Tianqing Pharmaceutical Group Co. Ltd. ( CT Tianqing ), a member company of the Group, and Beijing-based Genetron Holdings Limited (NASDAQ: GTH) signed a strategic cooperation agreement on early screening of liver cancer. The two parties will work together in the next three years in selected areas in the country to serve those at high risk of developing liver cancer, including Hepa ....

Chia Tai , Kaifen Flurbiprofen Axetil , Deyou Pronase , Fosaprepitant Dimeglumine , Forbes Asia , Debaian Zepolas Flurbiprofen Cataplasms , Andxian Lenalidomide , Tenofovir Disoproxil Fumarate , Shanqi Fosaprepitant Dimeglumine , Qianping Bortezomib , Sino Biopharm , Weishou Azacitidine , Anyue Pomalidomide , Acelate Ringer , Qingkeshu Abiraterone , Chia Tai Jiuli , Sino Biopharmaceutical , Tianqing Pharmaceutical Group Co , Tide Pharmaceutical Co , Asia Corporate News Network , Drug Administration , Sino Biopharmaceutical Limited , National Reimbursement Drug List , European Union , Hang Seng China Enterprises Index , Technological Development Area ,